Vivesto is a development company working to create new treatment options for humans and animals with hard-to-treat cancers. The company develops projects with the potential to offer new therapeutic alternatives in areas with significant medical needs. Vivesto possesses the capacity and expertise to develop drugs from early research to the clinic. Late-stage development and commercialization are intended to be pursued through partnerships with other pharmaceutical companies.

Vivesto’s veterinary medicine portfolio currently comprises the veterinary oncology program Paccal Vet. A clinical pilot study is ongoing for treatment of dogs with hemangiosarcoma (HSA) in the spleen after splenectomy using the product candidate Paccal Vet dog. Additionally, a dose-finding study is being conducted in cats with solid cancer tumors using the product candidate Paccal Vet cat.

Vivesto’s human pharmaceuticals portfolio includes the cancer program Cantrixil, aimed at treating various forms of hematological cancer – areas with major medical needs and significant commercial potential. The cancer product Apealea previously had market approval in the EU for the treatment of adult patients suffering a first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer, in combination with carboplatin. Apealea has been out-licensed to Zhida with rights to develop and commercialize the product in China, Hongkong, Macau, and Taiwan. Discussions are ongoing with potential partners for Apealea in other regions.